Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

OMVax Inc
Profile last edited on: 12/2/2021      CAGE: 7CGX6      UEI: MKQKRT751Q19

Business Identifier: Next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups
Year Founded
2015
First Award
2016
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1700 Owens Street Suite 515
San Francisco, CA 94158
   (415) 554-8170
   N/A
   N/A
Location: Single
Congr. District: 11
County: San Francisco

Public Profile

Flying somewhat under the radar OMVax Inc is working on the development of a next-generation meningcococcal serogroup B vaccine with improved effectiveness for all age groups - inclding infants and toddlers - groups partiuclarly at risk .

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
1
Conversion Rate
100.00%
Phase I Dollars
$299,970
Phase II Dollars
$3,000,000
Total Awarded
$3,299,970

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 2 NIH $3,299,970
Project Title: A Universal Vaccine for the Prevention of Meningococcal Meningitis in Africa

Key People / Management

  Alejandro Bolanos -- Research Associate

  Timothy Cumagun

  Ella Garcia

  Serena Giuntini -- Director, Vaccines R&D

  Gregory Robert Moe -- Chief Scientific Officer and Co-Founder

  Adan Ramos -- Research Associate

  William J Rutter

Company News

There are no news available.